BPMC
Price
$100.31
Change
-$1.20 (-1.18%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
6.65B
69 days until earnings call
CDXS
Price
$2.46
Change
+$0.12 (+5.13%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
202.97M
70 days until earnings call
Interact to see
Advertisement

BPMC vs CDXS

Header iconBPMC vs CDXS Comparison
Open Charts BPMC vs CDXSBanner chart's image
Blueprint Medicines
Price$100.31
Change-$1.20 (-1.18%)
Volume$6.97K
Capitalization6.65B
Codexis
Price$2.46
Change+$0.12 (+5.13%)
Volume$11.32K
Capitalization202.97M
BPMC vs CDXS Comparison Chart
Loading...
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BPMC vs. CDXS commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BPMC is a Buy and CDXS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (BPMC: $101.51 vs. CDXS: $2.34)
Brand notoriety: BPMC and CDXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BPMC: 51% vs. CDXS: 88%
Market capitalization -- BPMC: $6.65B vs. CDXS: $202.97M
BPMC [@Biotechnology] is valued at $6.65B. CDXS’s [@Biotechnology] market capitalization is $202.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BPMC’s FA Score shows that 0 FA rating(s) are green whileCDXS’s FA Score has 0 green FA rating(s).

  • BPMC’s FA Score: 0 green, 5 red.
  • CDXS’s FA Score: 0 green, 5 red.
According to our system of comparison, both BPMC and CDXS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BPMC’s TA Score shows that 6 TA indicator(s) are bullish while CDXS’s TA Score has 4 bullish TA indicator(s).

  • BPMC’s TA Score: 6 bullish, 4 bearish.
  • CDXS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BPMC is a better buy in the short-term than CDXS.

Price Growth

BPMC (@Biotechnology) experienced а +4.10% price change this week, while CDXS (@Biotechnology) price change was -5.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.82%. For the same industry, the average monthly price growth was +7.45%, and the average quarterly price growth was -1.67%.

Reported Earning Dates

BPMC is expected to report earnings on Jul 30, 2025.

CDXS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.82% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BPMC($6.65B) has a higher market cap than CDXS($203M). BPMC YTD gains are higher at: 16.384 vs. CDXS (-50.943). CDXS has higher annual earnings (EBITDA): -53.41M vs. BPMC (-66.42M). BPMC has more cash in the bank: 576M vs. CDXS (73.5M). CDXS has less debt than BPMC: CDXS (59.9M) vs BPMC (467M). BPMC has higher revenues than CDXS: BPMC (562M) vs CDXS (59.3M).
BPMCCDXSBPMC / CDXS
Capitalization6.65B203M3,277%
EBITDA-66.42M-53.41M124%
Gain YTD16.384-50.943-32%
P/E RatioN/AN/A-
Revenue562M59.3M948%
Total Cash576M73.5M784%
Total Debt467M59.9M780%
FUNDAMENTALS RATINGS
BPMC vs CDXS: Fundamental Ratings
BPMC
CDXS
OUTLOOK RATING
1..100
1115
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
69100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4364
P/E GROWTH RATING
1..100
59100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (45) in the Chemicals Specialty industry is somewhat better than the same rating for BPMC (79) in the Biotechnology industry. This means that CDXS’s stock grew somewhat faster than BPMC’s over the last 12 months.

BPMC's Profit vs Risk Rating (69) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that BPMC’s stock grew similarly to CDXS’s over the last 12 months.

BPMC's SMR Rating (100) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that BPMC’s stock grew similarly to CDXS’s over the last 12 months.

BPMC's Price Growth Rating (43) in the Biotechnology industry is in the same range as CDXS (64) in the Chemicals Specialty industry. This means that BPMC’s stock grew similarly to CDXS’s over the last 12 months.

BPMC's P/E Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for CDXS (100) in the Chemicals Specialty industry. This means that BPMC’s stock grew somewhat faster than CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BPMCCDXS
RSI
ODDS (%)
Bearish Trend 2 days ago
73%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 7 days ago
73%
Bullish Trend 15 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
73%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
BPMC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EDEN113.440.04
+0.04%
iShares MSCI Denmark ETF
HEAT25.75N/A
N/A
Touchstone Climate Transition ETF
FLMI24.11-0.07
-0.29%
Franklin Dynamic Municipal Bond ETF
TMFE27.23-0.41
-1.48%
Motley Fool Capital Efficiency 100 ETF
VTHR257.62-4.11
-1.57%
Vanguard Russell 3000 ETF

BPMC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BPMC has been loosely correlated with ORIC. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BPMC jumps, then ORIC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BPMC
1D Price
Change %
BPMC100%
-1.45%
ORIC - BPMC
43%
Loosely correlated
+3.53%
ARQT - BPMC
42%
Loosely correlated
-5.17%
AXON - BPMC
41%
Loosely correlated
-0.99%
IDYA - BPMC
41%
Loosely correlated
-2.45%
BBIO - BPMC
41%
Loosely correlated
-2.58%
More